COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Yotam Bronstein; Roi Gat; Shai Levi; Yael C. Cohen; Efrat Luttwak; Noam Benyamini; Tamir Shragai; Roy Vitkon; Miriam Neaman; Nili Eilaty; Mor Levi; Svetlana Trestman; Chava Perry; Yair Herishanu; Irit Avivi

doi:10.1016/j.ccell.2022.04.015

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

Yotam Bronstein, Roi Gat, Shai Levi, Yael C. Cohen, Efrat Luttwak, Noam Benyamini, Tamir Shragai, Roy Vitkon, Miriam Neaman, Nili Eilaty, Mor Levi, Svetlana Trestman, Chava Perry, Yair Herishanu, Irit Avivi^*

^*Corresponding author for this work

Clinical Departments

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	578-580
Number of pages	3
Journal	Cancer Cell
Volume	40
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2022.04.015
State	Published - 13 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2022.04.015

Cite this

@article{d6f9c5835fae4d50bd0ab9b58e4ca36f,

title = "COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge",

author = "Yotam Bronstein and Roi Gat and Shai Levi and Cohen, {Yael C.} and Efrat Luttwak and Noam Benyamini and Tamir Shragai and Roy Vitkon and Miriam Neaman and Nili Eilaty and Mor Levi and Svetlana Trestman and Chava Perry and Yair Herishanu and Irit Avivi",

note = "Funding Information: Y.H. reports honoraria from Janssen, AbbVie, Roche, Astra-Zeneca, and Medision, not related to this study. I.A. reports speaker's bureau for Gilead, Novartis, AbbVie, and Janssen and served as a consultant for Janssen, MSD, AbbVie, Novartis, and Roche, not related to this study. The other authors declare no competing interests.",

year = "2022",

month = jun,

day = "13",

doi = "10.1016/j.ccell.2022.04.015",

language = "אנגלית",

volume = "40",

pages = "578--580",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

AU - Bronstein, Yotam

AU - Gat, Roi

AU - Levi, Shai

AU - Cohen, Yael C.

AU - Luttwak, Efrat

AU - Benyamini, Noam

AU - Shragai, Tamir

AU - Vitkon, Roy

AU - Neaman, Miriam

AU - Eilaty, Nili

AU - Levi, Mor

AU - Trestman, Svetlana

AU - Perry, Chava

AU - Herishanu, Yair

AU - Avivi, Irit

N1 - Funding Information: Y.H. reports honoraria from Janssen, AbbVie, Roche, Astra-Zeneca, and Medision, not related to this study. I.A. reports speaker's bureau for Gilead, Novartis, AbbVie, and Janssen and served as a consultant for Janssen, MSD, AbbVie, Novartis, and Roche, not related to this study. The other authors declare no competing interests.

PY - 2022/6/13

Y1 - 2022/6/13

UR - http://www.scopus.com/inward/record.url?scp=85131571914&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2022.04.015

DO - 10.1016/j.ccell.2022.04.015

M3 - מזכר

C2 - 35477028

AN - SCOPUS:85131571914

VL - 40

SP - 578

EP - 580

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

UN SDGs

Access to Document

Other files and links

Cite this